## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.8% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($95.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. California Public Employees Retirement System Purchases 563,779 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251207T100754 | Bullish | Relevance: 99%
- The California Public Employees Retirement System (CalPERS) significantly increased its stake in Medtronic PLC, purchasing 563,779 additional shares in Q2 2025, bringing its total holdings to 3,230,852 shares valued at approximately $281.6 million. Medtronic stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44. The company recently surpassed quarterly earnings and revenue estimates and announced a quarterly dividend, indicating strong financial health and positive outlook.

**2. The Year Medtronic Set an Example for Supply Chain Optimization**
- Source: Medical Device and Diagnostic industry | 20251209T001413 | Bullish | Relevance: 99%
-  Medtronic has been named the 2025 Medtech Company of the Year by MD+DI editors for its exemplary efforts in building supply chain resilience amidst a challenging trade environment. The company underwent a significant transformation, consolidating its manufacturing and supply chain organizations and leveraging AI to improve forecast accuracy by up to 15%. This strategic overhaul has not only enhanced operational efficiencies and protected margins but also allowed for reinvestment in innovation, ultimately aiming to improve patient care.

**3. Medtronic PLC $MDT Shares Bought by Cary Street Partners Financial LLC**
- Source: MarketBeat | 20251207T090818 | Bullish | Relevance: 99%
-  Cary Street Partners Financial LLC significantly increased its stake in Medtronic PLC, purchasing an additional 15,663 shares, bringing their total holdings to 97,941 shares valued at $8.54 million. This move aligns with broader institutional interest, as major investors like Vanguard and Norges Bank have also boosted or initiated positions in the medical technology company. Medtronic recently exceeded quarterly earnings estimates, provided strong FY2026 guidance, and declared an attractive quarterly dividend, leading analysts to maintain a "Moderate Buy" consensus rating with a target price of $110.44.

**4. Thematics Asset Management Sells 13,298 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251208T121527 | Bullish | Relevance: 99%
-  Thematics Asset Management reduced its stake in Medtronic PLC by selling 13,298 shares, now holding 184,899 shares valued at $16.12 million; however, many other institutional investors increased their positions. Medtronic reported strong quarterly earnings, beating analyst estimates for EPS and revenue, and announced a quarterly dividend of $0.71. The company's stock has also received updated price targets and ratings from several analyst firms.

**5. First Trust Advisors LP Sells 103,019 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251207T111333 | Somewhat-Bullish | Relevance: 98%
-  First Trust Advisors LP reduced its holdings in Medtronic PLC by 10.9%, selling 103,019 shares and retaining 841,814 shares. Medtronic reported stronger-than-expected quarterly earnings and revenue, with FY2026 guidance set at $5.620-$5.660 EPS, and announced a quarterly dividend of $0.71. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $127.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 6.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.78% (CS: 16) | Weak |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.096x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.62
- **Stop Loss:** $95.90 (3.7% risk)
- **Target:** $103.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 80
- **Position Value:** $7,969.60
- **Portfolio %:** 7.97%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*